Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04205552
Title Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients (NEOpredict)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital, Essen
Indications

lung non-small cell carcinoma

Therapies

Nivolumab + Relatlimab

Nivolumab

Age Groups: adult | senior
Covered Countries DEU | BEL


No variant requirements are available.